Rejoni completes patient enrollment in pivotal clinical study of a Novel Treatment for the Prevention of Intrauterine Adhesions, the Juveena® Hydrogel System.

[#item_full_content]BEDFORD, Mass.–(BUSINESS WIRE)–Rejoni, Inc., a privately held clinical-stage company, today announced the completion of enrollment of 150 patients in the Juveena Hydrogel pivotal clinical study. This announcement marks a significant achievement in the field of women’s health, particularly concerning the prevention of intrauterine adhesions (IUAs) that can result in a condition known as “Asherman’s Syndrome”. IUAs are bands of fibrous tissue that form in the uterus, often in response to intrau